ACADIA Pharmaceuticals Investor Relations Material
Latest events
Q4 2023
ACADIA Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from ACADIA Pharmaceuticals Inc
Access all reports
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on improving the lives of patients with serious central nervous system disorders. The Company has a clinical program to assess the safety, efficacy and pharmacokinetic profile of pimavanserin (RE-021), an investigational drug that acts as a selective serotonin 5-hydroxytryptamine 2A receptor inverse agonist (SSRI) to study the central serotonergic system pharmacology and physiology in healthy volunteers and patients with Parkinson's disease psychosis (PDP).
Key slides for ACADIA Pharmaceuticals Inc
Q2 2023
ACADIA Pharmaceuticals Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
ACADIA Pharmaceuticals Inc
Latest articles
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
John Elkann: Leading Stellantis, Ferrari, and Exor to New Heights
As the Chairman of Stellantis and Ferrari and CEO of Exor, John Elkann is arguably the most influential person in the global automotive sector.
26 Mar 2024
Ticker symbol
Country
🇺🇸 United States